Oncology
Metastatic Tumors
0
Pipeline Programs↗
6
Active Trials↗
7
Companies Involved↗
Metastatic Tumors is an early-stage landscape with 0 programs across 7 companies. The most active players are Roche, AstraZeneca, AbbVie.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Completed10 · 56%
Recruiting5 · 28%
Terminated1 · 6%
Unknown status1 · 6%
Active, not recruiting1 · 6%
Clinical Trials
Trial Activity
18 trials
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors
Active, not recruiting·—·Phase 3·NCT03721341·204 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)